At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 566 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
In Brief
A Phase 4 clinical trial evaluating Ixekizumab and Adalimumab for Psoriatic Arthritis. Completed, enrolled 566 participants across 131 sites in 22 countries.
Detailed Summary
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesArgentina, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, India, Israel, Italy, Mexico, Netherlands, Poland, South Africa, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartAug 2017
Primary CompletionNov 2018
Study CompletionSep 2019
TodayJul 2026
First PostedMay 12, 2017
Enrollment StartAug 24, 2017
Primary CompletionNov 15, 2018
Study CompletionSep 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.1 years ago
Interventions
Ixekizumabdrug
Administered SC
Adalimumabdrug
Administered SC